PET Imaging of Atherosclerotic Disease: Advancing Plaque Assessment from Anatomy to Pathophysiology

Current Atherosclerosis Reports

Volumn 18, Issue 6, 2016, Pages

  Evans, Nicholas R ^a   Tarkin, Jason M ^a   Chowdhury, Mohammed M ^b   Warburton, Elizabeth A ^a   Rudd, James H F ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Atherosclerosis; Carotid stenosis; Coronary artery disease; Positron emission tomography

Indexed keywords

CARRIER PROTEIN; COPPER [1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID] OCTREOTATE[DEXTRO 1 PHENYLALANINE 3 TYROSINE] CU 64; DALCETRAPIB; FLUORODEOXYGLUCOSE F 18; GALLIUM [1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID] OCTREOTATE[DEXTRO 1 PHENYLALANINE 3 TYROSINE] GA 68; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; RADIOLIGAND; SODIUM FLUORIDE F 18; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG SCREENING; HUMAN; HYPOXIA; NONHUMAN; PARTIAL VOLUME CORRECTION; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROTEIN TARGETING; QUANTITATIVE DIAGNOSIS; RADIOLOGICAL PARAMETERS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; STANDARDIZED UPTAKE VALUE; TISSUE TO BACKGROUND RATIO; DIAGNOSTIC IMAGING; PATHOLOGY;

ATHEROSCLEROSIS; HUMANS; PLAQUE, ATHEROSCLEROTIC; POSITRON-EMISSION TOMOGRAPHY;

EID: 84964269897     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-016-0584-3     Document Type: Review

References (108)

1. Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res. 2014;114(12):1867–79.
2. Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Intern Med. 2015;278(5):483–93.
3. Chung JW, Park SH, Kim N, et al. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification and vascular territory of ischemic stroke lesions diagnosed by diffusion-weighted imaging. J Am Heart Assoc. 2014;3(4), e001119.
4. Baber U, Mehran R, Sartori S, et al. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study. J Am Coll Cardiol. 2015;65(11):1065–74.
5. Sillesen H, Muntendam P, Adourian A, et al. Carotid plaque burden as a measure of subclinical atherosclerosis: comparison with other tests for subclinical arterial disease in the High Risk Plaque BioImage study. JACC Cardiovasc Imaging. 2012;5(7):681–9.
6. Bjerrum IS, Sand NP, Poulsen MK, et al. Non-invasive assessments reveal that more than half of randomly selected middle-aged individuals have evidence of subclinical atherosclerosis: a DanRisk substudy. Int J Cardiovasc Imaging. 2013;29(2):301–8.
7. Howard DP, van Lammeren GW, Rothwell PM, et al. Symptomatic carotid atherosclerotic disease: correlations between plaque composition and ipsilateral stroke risk. Stroke. 2015;46(1):182–9.
8. Freilinger TM, Schindler A, Schmidt C, et al. Prevalence of nonstenosing, complicated atherosclerotic plaques in cryptogenic stroke. JACC Cardiovasc Imaging. 2012;5(4):397–405.
9. Gupta A, Gialdini G, Lerario MP, et al. Magnetic resonance angiography detection of abnormal carotid artery plaque in patients with cryptogenic stroke. J Am Heart Assoc. 2015;4(6), e002012.
10. Mann JM, Davies MJ. Vulnerable plaque. Relation of characteristics to degree of stenosis in human coronary arteries. Circulation. 1996;94(5):928–31.
11. Oemrawsingh RM, Cheng JM, Garcia-Garcia HM, et al. Near-infrared spectroscopy predicts cardiovascular outcome in patients with coronary artery disease. J Am Coll Cardiol. 2014;64(23):2510–8.
12. Ota H, Magalhaes MA, Torguson R, et al. The influence of lipid-containing plaque composition assessed by near-infrared spectroscopy on coronary lesion remodelling. Eur Heart J Cardiovasc Imaging. 2015. doi:10.1093/ehjci/jev221.
13. Motoyama S, Ito H, Sarai M, et al. Plaque characterization by coronary computed tomography angiography and the likelihood of acute coronary events in mid-term follow-up. J Am Coll Cardiol. 2015;66(4):337–46.
14. Puchner SB, Liu T, Mayrhofer T, et al. High-risk plaque detected on coronary CT angiography predicts acute coronary syndromes independent of significant stenosis in acute chest pain: results from the ROMICAT-II trial. J Am Coll Cardiol. 2014;64(7):684–92.
15. Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48(9):1818–24.
16. Silberstein EB. Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine. J Nucl Med. 1998;39(12):2190–2.
17. Yun M, Yeh D, Araujo LI, Jang S, Newberg A, Alavi A. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med. 2001;26(4):314–9.
18. Rudd JHF, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105(23):2708–11.
19. Skagen K, Johnsrud K, Evensen K, et al. Carotid plaque inflammation assessed with (18)F-FDG PET/CT is higher in symptomatic compared with asymptomatic patients. Int J Stroke. 2015;10(5):730–6. A recent large study demonstrating the utility of FDG-PET to differentiate between symptomatic and asymptomatic carotid atheroma.
20. Hyafil F, Cornily JC, Rudd JH, Machac J, Feldman LJ, Fayad ZA. Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: a comparison with 18F-FDG PET/CT and histology. J Nucl Med. 2009;50(6):959–65.
21. Davies JR, Izquierdo-Garcia D, Rudd JH, et al. FDG-PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis. Int J Cardiovasc Imaging. 2010;26(1):41–8.
22. Liu J, Kerwin WS, Caldwell JH, et al. High resolution FDG-microPET of carotid atherosclerosis: plaque components underlying enhanced FDG uptake. Int J Cardiovasc Imaging. 2015. doi:10.1007/s10554-015-0739-2.
23. Davies JR, Rudd JH, Fryer TD, et al. Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke. 2005;36(12):2642–7.
24. Arauz A, Hoyos L, Zenteno M, Mendoza R, Alexanderson E. Carotid plaque inflammation detected by 18F-fluorodeoxyglucose-positron emission tomography. Pilot study. Clin Neurol Neurosurg. 2007;109(5):409–12.
25. Tahara N, Kai H, Nakaura H, et al. The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose-positron emission tomography. Eur Heart J. 2007;28(18):2243–8.
26. Figueroa AL, Subramanian SS, Cury RC, et al. Distribution of inflammation within carotid atherosclerotic plaques with high-risk morphological features: a comparison between positron emission tomography activity, plaque morphology, and histopathology. Circ Cardiovasc Imaging. 2012;5(1):69–77.
27. Silvera SS, Aidi HE, Rudd JH, et al. Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. Atherosclerosis. 2009;207(1):139–43.
28. Marnane M, Merwick A, Sheehan OC, et al. Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann Neurol. 2012;71(5):709–18.
29. Moustafa RR, Izquierdo-Garcia D, Fryer TD, et al. Carotid plaque inflammation is associated with cerebral microembolism in patients with recent transient ischemic attack or stroke: a pilot study. Circ Cardiovasc Imaging. 2010;3(5):536–41. Study demonstrates how inflammation as measured by FDG-PET is associated with plaque instability and microembolic events on transcranial Doppler.
30. Rudd JH, Myers KS, Bansilal S, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging. 2009;2(2):107–15. Study demonstrates the systemic nature of atheromatous inflammation as measured by FDG-PET.
31. Joshi NV, Toor I, Shah AS, et al. Systemic atherosclerotic inflammation following acute myocardial infarction: myocardial infarction begets myocardial infarction. J Am Heart Assoc. 2015;4(9), e001956.
32. Kim S, Lee S, Kim JB, et al. Concurrent carotid inflammation in acute coronary syndrome as assessed by (18)F-FDG PET/CT: a possible mechanistic link for ischemic stroke. J Stroke Cerebrovasc Dis. 2015;24(11):2547–54.
33. Yoo HJ, Kim S, Hwang SY, et al. Vascular inflammation in metabolically abnormal but normal-weight and metabolically healthy obese individuals analyzed with (1)(8)F-fluorodeoxyglucose positron emission tomography. Am J Cardiol. 2015;115(4):523–8.
34. Chróinín DN, Marnane M, Akijian L, et al. Serum lipids associated with inflammation-related PET-FDG uptake in symptomatic carotid plaque. Neurology. 2014;82(19):1693–9.
35. Kaida H, Tahara N, Tahara A, et al. Positive correlation between malondialdehyde-modified low-density lipoprotein cholesterol and vascular inflammation evaluated by 18F-FDG PET/CT. Atherosclerosis. 2014;237(2):404–9.
36. Tonetti MS, D’Aiuto F, Nibali L, et al. Treatment of periodontitis and endothelial function. N Engl J Med. 2007;356(9):911–20.
37. Subramanian S, Emami H, Vucic E, et al. High-dose atorvastatin reduces periodontal inflammation: a novel pleiotropic effect of statins. J Am Coll Cardiol. 2013;62(25):2382–91.
38. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387–97.
39. Sarwar N, Butterworth AS, Freitag DF, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379(9822):1205–13.
40. Meuwese MC, Stroes ES, Hazen SL, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;50(2):159–65.
41. Duivenvoorden R, Mani V, Woodward M, et al. Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study. JACC Cardiovasc Imaging. 2013;6(10):1087–94.
42. Yoo HJ, Kim S, Park MS, et al. Vascular inflammation stratified by C-reactive protein and low-density lipoprotein cholesterol levels: analysis with 18F-FDG PET. J Nucl Med. 2011;52(1):10–7.
43. Abdelbaky A, Corsini E, Figueroa AL, et al. Focal arterial inflammation precedes subsequent calcification in the same location: a longitudinal FDG-PET/CT study. Circ Cardiovasc Imaging. 2013;6(5):747–54.
44. Joshi FR, Rajani NK, Abt M, et al. Does vascular calcification accelerate inflammation?: a substudy of the dal-PLAQUE Trial. J Am Coll Cardiol. 2016;67(1):69–78.
45. Abela GS, Aziz K. Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events—a novel insight into plaque rupture by scanning electron microscopy. Scanning. 2006;28(1):1–10.
46. Vedre A, Pathak DR, Crimp M, Lum C, Koochesfahani M, Abela GS. Physical factors that trigger cholesterol crystallization leading to plaque rupture. Atherosclerosis. 2009;203(1):89–96.
47. Abela GS, Aziz K, Vedre A, Pathak DR, Talbott JD, Dejong J. Effect of cholesterol crystals on plaques and intima in arteries of patients with acute coronary and cerebrovascular syndromes. Am J Cardiol. 2009;103(7):959–68.
48. Patel R, Janoudi A, Vedre A, et al. Plaque rupture and thrombosis are reduced by lowering cholesterol levels and crystallization with ezetimibe and are correlated with fluorodeoxyglucose positron emission tomography. Arterioscler Thromb Vasc Biol. 2011;31(9):2007–14.
49. Rudd JH, Myers KS, Bansilal S, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008;49(6):871–8.
50. Cai J, Hatsukami TS, Ferguson MS, et al. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation. 2005;112(22):3437–44.
51. Takaya N, Yuan C, Chu B, et al. Association between carotid plaque characteristics and subsequent ischemic cerebrovascular events: a prospective assessment with MRI—initial results. Stroke. 2006;37(3):818–23.
52. Laitinen I, Marjamaki P, Nagren K, et al. Uptake of inflammatory cell marker [11C]PK11195 into mouse atherosclerotic plaques. Eur J Nucl Med Mol Imaging. 2009;36(1):73–80.
53. Gaemperli O, Shalhoub J, Owen DR, et al. Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. Eur Heart J. 2012;33(15):1902–10.
54. Fujimura Y, Hwang PM, Trout Iii H, et al. Increased peripheral benzodiazepine receptors in arterial plaque of patients with atherosclerosis: an autoradiographic study with [(3)H]PK 11195. Atherosclerosis. 2008;201(1):108–11.
55. Bird JL, Izquierdo-Garcia D, Davies JR, et al. Evaluation of translocator protein quantification as a tool for characterising macrophage burden in human carotid atherosclerosis. Atherosclerosis. 2010;210(2):388–91.
56. Dickens AM, Vainio S, Marjamaki P, et al. Detection of microglial activation in an acute model of neuroinflammation using PET and radiotracers 11C-(R)-PK11195 and 18F-GE-180. J Nucl Med. 2014;55(3):466–72.
57. Boutin H, Murray K, Pradillo J, et al. 18F-GE-180: a novel TSPO radiotracer compared to 11C-R-PK11195 in a preclinical model of stroke. Eur J Nucl Med Mol Imaging. 2015;42(3):503–11.
58. Kreisl WC, Jenko KJ, Hines CS, et al. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab. 2013;33(1):53–8.
59. Guo Q, Colasanti A, Owen DR, et al. Quantification of the specific translocator protein signal of 18F-PBR111 in healthy humans: a genetic polymorphism effect on in vivo binding. J Nucl Med. 2013;54(11):1915–23.
60. Lavisse S, Garcia-Lorenzo D, Peyronneau MA, et al. Optimized quantification of translocator protein radioligand (1)(8)F-DPA-714 uptake in the brain of genotyped healthy volunteers. J Nucl Med. 2015;56(7):1048–54.
61. Dalm VA, van Hagen PM, van Koetsveld PM, et al. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am J Physiol Endocrinol Metab. 2003;285(2):E344–53.
62. Armani C, Catalani E, Balbarini A, Bagnoli P, Cervia D. Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. J Leukoc Biol. 2007;81(3):845–55.
63. Mojtahedi A, Alavi A, Thamake S, et al. Assessment of vulnerable atherosclerotic and fibrotic plaques in coronary arteries using (68)Ga-DOTATATE PET/CT. Am J Nucl Med Mol Imaging. 2015;5(1):65–71.
64. Li X, Samnick S, Lapa C, et al. 68Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with18F-FDG, calcium burden and risk factors. EJNMMI Res. 2012;2(1):52.
65. Rominger A, Saam T, Vogl E, et al. In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors. J Nucl Med. 2010;51(2):193–7.
66. Rinne P, Hellberg S, Kiugel M, et al. Comparison of somatostatin receptor 2-targeting PET tracers in the detection of mouse atherosclerotic plaques. Mol Imaging Biol. 2015. doi:10.1007/s11307-015-0873-1.
67. Pedersen SF, Sandholt BV, Keller SH, et al. 64Cu-DOTATATE PET/MRI for detection of activated macrophages in carotid atherosclerotic plaques: studies in patients undergoing endarterectomy. Arterioscler Thromb Vasc Biol. 2015;35(7):1696–703.
68. Malmberg C, Ripa RS, Johnbeck CB, et al. 64Cu-DOTATATE for noninvasive assessment of atherosclerosis in large arteries and its correlation with risk factors: head-to-head comparison with 68Ga-DOTATOC in 60 patients. J Nucl Med. 2015;56(12):1895–900.
69. Kelly-Arnold A, Maldonado N, Laudier D, Aikawa E, Cardoso L, Weinbaum S. Revised microcalcification hypothesis for fibrous cap rupture in human coronary arteries. Proc Natl Acad Sci U S A. 2013;110(26):10741–6.
70. Chen W, Dilsizian V. Targeted PET/CT imaging of vulnerable atherosclerotic plaques: microcalcification with sodium fluoride and inflammation with fluorodeoxyglucose. Curr Cardiol Rep. 2013;15(6):364.
71. Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008;117(22):2938–48.
72. Aikawa E, Nahrendorf M, Figueiredo JL, et al. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation. 2007;116(24):2841–50.
73. Hawkins RA, Choi Y, Huang SC, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992;33(5):633–42.
74. Irkle A, Vesey AT, Lewis DY, et al. Identifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomography. Nat Commun. 2015;6:7495. Study provides histological validation of NaF-PET signal in atheromatous plaques.
75. Derlin T, Richter U, Bannas P, et al. Feasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaque. J Nucl Med. 2010;51(6):862–5.
76. Morbelli S, Fiz F, Piccardo A, et al. Divergent determinants of 18F-NaF uptake and visible calcium deposition in large arteries: relationship with Framingham risk score. Int J Cardiovasc Imaging. 2014;30(2):439–47.
77. Fiz F, Morbelli S, Piccardo A, et al. 18F-NaF uptake by the atherosclerotic plaque at PET/CT imaging: inverse correlation between calcification density and mineral metabolic activity. J Nucl Med. 2015. doi:10.2967/jnumed.115.154229.
78. Derlin T, Wisotzki C, Richter U, et al. In vivo imaging of mineral deposition in carotid plaque using 18F-sodium fluoride PET/CT: correlation with atherogenic risk factors. J Nucl Med. 2011;52(3):362–8.
79. Derlin T, Toth Z, Papp L, et al. Correlation of inflammation assessed by 18F-FDG PET, active mineral deposition assessed by 18F-fluoride PET, and vascular calcification in atherosclerotic plaque: a dual-tracer PET/CT study. J Nucl Med. 2011;52(7):1020–7.
80. Dweck MR, Chow MW, Joshi NV, et al. Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol. 2012;59(17):1539–48.
81. Joshi NV, Vesey AT, Williams MC, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2014;383(9918):705–13. Key paper demonstrating utility of NaF-PET for detection of vulnerable coronary atherosclerotic plaques.
82. Quirce R, Martinez-Rodriguez I, De Arcocha TM, et al. Contribution of 18F-sodium fluoride PET/CT to the study of the carotid atheroma calcification. Rev Esp Med Nucl Imagen Mol. 2013;32(1):22–5.
83. Rubeaux M, Joshi NV, Dweck MR, et al. Motion correction of 18F-NaF PET for imaging coronary atherosclerotic plaques. J Nucl Med. 2016;57(1):54–9.
84. Zemplenyi T, Crawford DW, Cole MA. Adaptation to arterial wall hypoxia demonstrated in vivo with oxygen microcathodes. Atherosclerosis. 1989;76(2–3):173–9.
85. Leppanen O, Bjornheden T, Evaldsson M, Boren J, Wiklund O, Levin M. ATP depletion in macrophages in the core of advanced rabbit atherosclerotic plaques in vivo. Atherosclerosis. 2006;188(2):323–30.
86. Tawakol A, Singh P, Mojena M, et al. HIF-1alpha and PFKFB3 mediate a tight relationship between proinflammatory activation and anerobic metabolism in atherosclerotic macrophages. Arterioscler Thromb Vasc Biol. 2015;35(6):1463–71.
87. Lee SJ, Thien Quach CH, Jung KH, et al. Oxidized low-density lipoprotein stimulates macrophage 18F-FDG uptake via hypoxia-inducible factor-1alpha activation through Nox2-dependent reactive oxygen species generation. J Nucl Med. 2014;55(10):1699–705.
88. Mateo J, Izquierdo-Garcia D, Badimon JJ, Fayad ZA, Fuster V. Noninvasive assessment of hypoxia in rabbit advanced atherosclerosis using (1)(8)F-fluoromisonidazole positron emission tomographic imaging. Circ Cardiovasc Imaging. 2014;7(2):312–20.
89. Joshi FR, Manavaki R, Fryer TD, et al. Imaging of hypoxia and inflammation in carotid atherosclerosis with 18F-fluoromisonidazole and 18F-fluorodeoxyglucose positron emission tomography. Circulation. 2013;128 Suppl 22, A14673.
90. van der Valk FM, Sluimer JC, Voo SA, et al. In vivo imaging of hypoxia in atherosclerotic plaques in humans. JACC Cardiovasc Imaging. 2015;8(11):1340–1.
91. Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr. 1979;3(3):299–308.
92. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39(5):904–11.
93. Izquierdo-Garcia D, Davies JR, Graves MJ, et al. Comparison of methods for magnetic resonance-guided [18-F]fluorodeoxyglucose positron emission tomography in human carotid arteries: reproducibility, partial volume correction, and correlation between methods. Stroke. 2009;40(1):86–93.
94. Huet P, Burg S, Le Guludec D, Hyafil F, Buvat I. Variability and uncertainty of FDG PET imaging protocols for assessing inflammation in atherosclerosis: suggestions for improvement. J Nucl Med. 2015. doi:10.2967/jnumed.114.142596.
95. Niccoli Asabella A, Ciccone MM, Cortese F, et al. Higher reliability of 18F-FDG target background ratio compared to standardized uptake value in vulnerable carotid plaque detection: a pilot study. Ann Nucl Med. 2014;28(6):571–9.
96. Oh M, Kim JY, Shin KH, et al. Imaging atherosclerosis in the carotid arteries with F-18-Fluoro-2-deoxy-D-glucose positron emission tomography: effect of imaging time after injection on quantitative measurement. Nucl Med Mol Imaging. 2010;44(4):261–6.
97. Derlin T, Habermann CR, Hahne JD, et al. Quantification of [18F]-FDG uptake in atherosclerotic plaque: impact of renal function. Ann Nucl Med. 2011;25(8):586–91.
98. Bucerius J, Hyafil F, Verberne HJ, et al. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis. Eur J Nucl Med Mol Imaging. 2015. doi:10.1007/s00259-015-3259-3.
99. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48(9):1825–31.
100. Tawakol A, Fayad ZA, Mogg R, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol. 2013;62(10):909–17.
101. Wu YW, Kao HL, Huang CL, et al. The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. Eur J Nucl Med Mol Imaging. 2012;39(3):399–407.
102. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011;378(9802):1547–59.
103. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–99.
104. Emami H, Vucic E, Subramanian S, et al. The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial. Atherosclerosis. 2015;240(2):490–6.
105. Calcagno C, Ramachandran S, Izquierdo-Garcia D, et al. The complementary roles of dynamic contrast-enhanced MRI and 18F-fluorodeoxyglucose PET/CT for imaging of carotid atherosclerosis. Eur J Nucl Med Mol Imaging. 2013;40(12):1884–93.
106. Saito H, Kuroda S, Hirata K, et al. Validity of dual MRI and F-FDG PET imaging in predicting vulnerable and inflamed carotid plaque. Cerebrovasc Dis. 2013;35(4):370–7.
107. Ripa RS, Knudsen A, Hag AM, et al. Feasibility of simultaneous PET/MR of the carotid artery: first clinical experience and comparison to PET/CT. Am J Nucl Med Mol Imaging. 2013;3(4):361–71.
108. Hyafil F, Schindler A, Sepp D, et al. High-risk plaque features can be detected in non-stenotic carotid plaques of patients with ischaemic stroke classified as cryptogenic using combined F-FDG PET/MR imaging. Eur J Nucl Med Mol Imaging. 2015. doi:10.1007/s00259-015-3201-8.